uniQure NV (QURE) Sees Strong Trading Volume
uniQure NV (NASDAQ:QURE) saw unusually-high trading volume on Monday . Approximately 266,372 shares were traded during trading, an increase of 5% from the previous session’s volume of 253,639 shares.The stock last traded at $9.19 and had previously closed at $8.58.
QURE has been the topic of several recent research reports. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a report on Thursday, June 30th. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a research report on Monday, July 18th. Jefferies Group reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. Finally, Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $29.10.
The firm’s market cap is $209.97 million. The company’s 50-day moving average price is $7.74 and its 200 day moving average price is $11.60.
uniQure NV (NASDAQ:QURE) last announced its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.10. On average, equities analysts predict that uniQure NV will post ($3.45) EPS for the current fiscal year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.